

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/622,745	08/22/2000	Anders Edlund	1103326-0633	2661
7.	590 11/28/2001			
White & Case			EXAMINER	
1155 Avenue of the Americas New York, NY 10036-2787			LANDSMAN, ROBERT	
	•		ART UNIT	PAPER NUMBER
			1647	
			DATE MAILED: 11/28/2001	

Please find below and/or attached an Office communication concerning this application or proceeding.

.						
		Application No.	Applicant(s)			
Office Antique Communication		09/622,745	EDLUND ET AL.			
	Office Action Summary	Examiner	Art Unit			
		Robert Landsman	1647			
Period fo	The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status						
1)⊠	Responsive to communication(s) filed on 22 A	<u>ugust 2000</u> .				
2a) <u></u> ☐	This action is FINAL . 2b)⊠ This	s action is non-final.				
3)□	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
4)⊠ Claim(s) <u>1-31</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5)	Claim(s) is/are allowed.					
6) ☐ Claim(s) is/are rejected.						
7)	Claim(s) is/are objected to.					
8)⊠	Claim(s) <u>1-31</u> are subject to restriction and/or e	lection requirement.				
Application	on Papers					
9) The specification is objected to by the Examiner.						
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.						
12)☐ The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
 Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
<u> </u>						
 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application). a) ☐ The translation of the foreign language provisional application has been received. 						
15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(
2) 🔲 Notice	of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (PTO-948) ation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal Pa	(PTO-413) Paper No(s) atent Application (PTO-152)			
S. Patent and Tra	James Office					

U.S. Patent and Trademark Office PTO-326 (Rev. 04-01) Application/Control Number: 09/622,745

Art Unit: 1647

on .

DETAILED ACTION

1. Lack of Unity

A. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to which the claims must be restricted.

Group I, claims 1-20, drawn to a nucleic acid molecule constituting a human $GABA_B$ receptor promoter P1a, a vector and host cell.

Group II, claim 21, drawn to a method of assay for GABA_B receptor promoter activity.

Group III, claims 22-27, drawn to a method of screening modulators of GABA_B receptor 1 transcription.

Group IV, claims 28-29, drawn to a transgenic non-human animal comprising $GABA_B$ receptor promoter nucleic acid.

Group V, claims 30-31, drawn to a method of screening modulators of $GABA_B$ using cells from transgenic animals.

The inventions listed in Groups I-V do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical feature for the following reasons:the special technical feature of Group I is a nucleic acid molecule constituting a human GABA_B receptor promotor P1a. The special technical feature of Group II is a method of assay for GABA_B receptor promoter activity. The special technical feature of Group III is a method of screening modulators of GABA_B receptor 1 transcription. The special technical feature of Group IV is a transgenic non-human animal. The special technical feature of Group V is a method of screening modulators of GABA_B using cells from transgenic animals. The special technical feature of each Group is not the same, or does not correspond to the special technical feature of any other Group. The products of Groups I-VII are structurally and functionally distinct and the methods of Groups II, III and V require different method steps and reagents for achieving different goals. The Groups are not linked by a special technical feature within the meaning of PCT Rule 13.2 so as to form a single inventive concept.

· ... · ·

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter and separate classification, a finding of lack of unity for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Advisory information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert Landsman whose telephone number is (703) 306-3407. The examiner can normally be reached on Monday - Friday from 8:00 AM to 5:00 PM (Eastern time) and alternate Fridays from 8:00 AM to 5:00 PM (Eastern time).

If attempts to reach the examiner by telephone are unsuccessful, the Examiner's supervisor, Gary Kunz, can be reached on (703) 308-4623.

Official papers filed by fax should be directed to (703) 308-4242. Fax draft or informal communications with the examiner should be directed to (703) 308-0294.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Robert Landsman, Ph.D. Patent Examiner Group 1600 November 21, 2001

SUPERVISORY PATERT FRATER 1600